Disease Overview：Primary aldosteronism（PA）
Primary aldosteronism (PA), also known as Conn’s syndrome, is a common and potentially curable cause of secondary hypertension, characterized by excessive, autonomous production of aldosterone from the adrenal cortex—most frequently due to an aldosterone-producing adenoma or bilateral adrenal hyperplasia. This hormonal excess leads to sodium retention, potassium wasting, suppressed renin activity, and progressive end-organ damage—including left ventricular hypertrophy, renal impairment, and increased cardiovascular morbidity. Diagnosis requires confirmatory testing (e.g., plasma aldosterone-to-renin ratio, saline infusion or captopril challenge tests) followed by adrenal vein sampling for lateralization and imaging (CT/MRI) to localize lesions. Definitive treatment hinges on accurate subtyping: unilateral disease typically warrants laparoscopic adrenalectomy with high rates of hypertension remission and hypokalemia resolution, while bilateral disease is managed medically with mineralocorticoid receptor antagonists such as spironolactone or eplerenone.
China offers distinct advantages for PA management: leading endocrinology centers—especially in Beijing, Shanghai, and Guangzhou—boast internationally trained specialists with extensive experience in adrenal venous sampling and minimally invasive adrenalectomy. Advanced imaging (3T MRI, dual-energy CT) and intraoperative cortisol/aldosterone monitoring enhance diagnostic precision and surgical outcomes. Published success rates exceed 90% for hypertension improvement post-adrenalectomy in unilateral cases, with robust long-term follow-up data. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising clinical standards or accreditation (many hospitals hold JCI or CAP certification). As a dedicated medical tourism agency, we facilitate seamless international care—handling hospital referrals, arranging pre-arrival diagnostics, coordinating multidisciplinary consultations, providing transparent, all-inclusive pricing, and offering end-to-end support from visa assistance to post-discharge follow-up.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Primary Aldosteronism (Endocrinology)
Non-Surgical / Medical Management
*Target Criteria:* Bilateral adrenal hyperplasia, unilateral disease in non-surgical candidates (e.g., elderly, high surgical risk), post-adrenalectomy residual hypertension/hypokalemia.
- •First-Line Medication (Spironolactone)
- *Monthly Drug Cost:* $8–$22 (generic; 20 mg × 30 tablets)
- •Confirmatory & Monitoring Labs (Per Episode)
- Confirmatory saline infusion test (SIT) or oral sodium loading: $110 - Serum potassium, creatinine, eGFR, UACR: $28
- •Imaging (Adrenal CT, non-contrast): $135
- •Annual Endocrine Follow-up (Consult + BP/K⁺ monitoring): $65/session
Surgical / Interventional Management
*Eligibility Criteria:* Unilateral aldosteronoma confirmed by adrenal vein sampling (AVS), age <75, no major cardiopulmonary contraindications, AVS lateralization ratio ≥4:1.
- •Adrenal Vein Sampling (AVS)
- AVS procedure (catheterization, bilateral adrenal sampling, cortisol/aldosterone assay): $1,280
- •Laparoscopic Adrenalectomy
- Post-op pathology + immunohistochemistry: $185 - 3-day hospital stay (ward): $420
- •Preoperative Workup (mandatory): ECG, echocardiogram, pulmonary function test, electrolyte panel: $295
Special / Complex Condition Management
- •Bilateral Disease with Refractory Hypertension: High-dose spironolactone + amiloride + ACEi/ARB + calcium channel blocker — annual drug cost: $140–$260
- •Renal Impairment (eGFR <60 mL/min): Eplerenone substitution (monitoring K⁺ every 2 weeks × 3 months): $190/month
- •Post-Adrenalectomy Persistent Hyperaldosteronism: Repeat AVS + contralateral adrenalectomy (if confirmed): $5,800–$7,100
Quick Selection Guide
- •<55 years, unilateral on CT + AVS-confirmed: Laparoscopic adrenalectomy — curative intent, long-term cost savings despite upfront $4,800–$6,000 investment.
- •≥65 years or significant comorbidities (COPD, HF, CKD): Spironolactone-based medical therapy — avoids procedural risk; total annual cost ~$320 (drugs + labs + follow-up).
- •Bilateral disease + severe hypokalemia: Spironolactone + amiloride + strict dietary Na⁺ restriction — avoids surgery; initial 3-month stabilization cost: $410.
- •Budget-constrained (<$500/year): Generic spironolactone + community hospital BP/K⁺ checks — minimum viable control at $110/year, but requires strict adherence and quarterly ARR retesting ($45/test) if clinical suspicion persists.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Primary aldosteronism Medical Vacation Packages
Curated transparent all-inclusive packages combining Primary aldosteronism treatment with China top medical destinations:
